The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...

Ms E performed a comprehensive breast examination and did not find a lump. She did, however, note that the patient’s breasts ...

Joan Carpenter, PhD, CRNP, ACHPN, FPCN, receives the 2024 Excellence in Research Award from the Gerontological Advanced Practice Nurses Association.

Among pediatric patients with available data, 72.2% (13/18) reported consistent headache relief and 36% (9/25) reported consistent freedom from headache. The Food and Drug Administration (FDA) has ...

The Horizon® 3.0 Inspire has a compact design allowing for easier portability. The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive ...

Reductions seen in pain, disability, and use of analgesic medications. HealthDay News — Virtual yoga classes may be a feasible, safe, and effective treatment option for chronic low back pain (CLBP), ...

With the arrival in California of dengue, a dangerous mosquito-borne disease present mainly in more tropical climates, public health authorities are deploying a range of strategies to beat back the ...

Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.

Credit: Getty Images. With the arrival in California of dengue, a dangerous mosquito-borne disease present mainly in more ...

Emrosi is expected to be available in the first quarter or early second quarter of 2025. The Food and Drug Administration has approved Emrosi ™ (minocycline hydrochloride extended-release capsules) ...

Those who switch to dual use or who maintain, increase smoking intensity have reduced rate of symptom resolution. HealthDay News — Transitioning from cigarettes to electronic cigarettes (e-cigarettes) ...

Researchers identified 1924 recurrent nephrolithiasis events among 14,456 weighted patients who used an SGLT-2 inhibitor compared with 853 events among the 5877 patients who used a GLP-1 RA.